"I would understand that the 'three attractive targets' are new programs which are additional to the existing programs including the PYC35 phylomer (extracellular?) which you have mentioned."
PYCAG5 for TBI the company was trying to parnter with big pharma or biotech early 2011 - not sure what's happening there with no further updates since succesfully demonstrating proof of concept but i'd assume it may be one of the "three" above.
Here's key paragraphs from it anyway -
Dr Watt indicated the average loss of neurons from the injured region treated with Phylomer PYCAG5 was less than a third of the average loss observed for mock-treated control animals, or animals treated with a non-Phylomer peptide.
“Furthermore this particular Phylomer was associated with the largest increase in axonal sprouting relative to neuronal loss at four and seven days post-injury, which could increase the likelihood of brain tissue recovery in the damaged area.”
"Phylogica is now pursuing partnering opportunities with major pharmaceutical and biotech companies for further development of its lead candidate, PYCAG5, and the Company’s other neuroprotective Phylomers. This out licensing strategy is consistent with Phylogica’s discovery alliance focused business model."
PYC Price at posting:
2.4¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)